Latest News and Updates
OCV Promotes Dr. Chris Bostick to General Partner
OCV Partners (“OCV”) announced today that Dr. Chris Bostick has been promoted to General Partner. Chris joined OCV in 2018 and has provided his expertise and leadership to all of our healthcare investments as well as contributing to many of our non-healthcare...
ByHeart Secures $90M Series B Financing and Achieves All of its Clinical Trial Endpoints
ByHeart - the only new entrant to the US market to build its infant formula recipe entirely from scratch - achieves all of its clinical trial endpoints in the largest and most comprehensive clinical trial from a new infant formula brand in 25 years, further cementing...
Invoice2go, an OCV portfolio company, to be acquired by Bill.com (NYSE: BILL) for $625 Million
Mobile-first AR solution empowers businesses to transact from anywhere.Expands Bill.com’s footprint to serve international markets. Read Full Story on Businesswire.com SAN JOSE, Calif.--(BUSINESS WIRE)--Bill.com (NYSE:BILL), a leading provider of cloud-based software...
ByHeart Completes Largest US Clinical Trial for a New Infant Formula Brand in the Last 25 Years Supporting their Innovation in Baby Nutrition
ByHeart is expected to be the first new entrant to the market to build its own manufacturing facility, supply chain and infant formula blend that is based on decades of breast milk research and modern advancements in nutrition science. NEW YORK, June 2,...
Orca AI, which puts computer vision onto cargo ships, raises $13M Series A funding
Tel Aviv’s Orca AI, a computer vision startup that can be retrofitted to cargo ships and improve navigation and collision avoidance, has raised $13 million in a Series A funding, taking its total raised to over $15.5 million. While most cargo ships carry security...
Finch Therapeutics Announces Pricing of Upsized Initial Public Offering
SOMERVILLE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally...
Praxis Precision Medicines Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
CAMBRIDGE, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by...
OSSIO Awarded FDA 510(k) Clearance for OSSIOfiber® Compression Screw Portfolio
Company Successfully Surpasses 1,000th Implantation Milestone for its Strong and Bio-integrative OSSIOfiber® Technology WOBURN, Mass.–(BUSINESS WIRE)–OSSIO, Inc., an orthopedic fixation technology company, today announced that its OSSIOfiber® Compression Screw...
OCV Partners Assist Portfolio Company Social Native in Acquiring Olapic to Create Next-Gen Creative Optimization Platform
LOS ANGELES–(BUSINESS WIRE)–Social Native, a marketplace technology company that empowers marketers to source and optimize visual content to improve brand awareness and performance, announced today the acquisition of Olapic, a leading user-generated, influencer, and...
OCV Partners Participates in Finch Therapeutics’ Oversubscribed $90 Million Financing to Advance its Pipeline of Investigational Oral Microbiome Drugs
Proceeds to support the advancement of lead candidate through the final stages of clinical development for recurrent C. difficile infection, and the advancement into the clinic of programs for autism spectrum disorder and chronic hepatitis B.Somerville, MA, September...
SafeBreach Raises $19 Million to Expand Channels, Accelerate Product Development
Experiencing rapid customer growth, the industry’s leading provider of breach-and-attack simulation will use the funding to accelerate the development of new product capabilities and services, expand strategic partnerships and grow its channel relationships with major...
OCV Partners Co-leads By Heart’s $70M Series A Financing Ahead of First Product Launch in 2021
Lead Investors Include Polaris Partners, D1 Capital Partners, and OCV Partners in the Over-Subscribed Round; Former Pfizer Baby Nutrition Leader, as well as Former CEO of J2 Global (What to Expect, BabyCenter and Everyday Health) Join the ByHeart Board of DirectorsNEW...
With our decades of company building experience, we look to create asymmetric advantages when backing winning teams.
